Kai Yeung, PharmD, PhD

“My work helps to maximize the benefit to society for every dollar spent on health care.”

Kai Yeung, PharmD, PhD

Assistant Investigator, Kaiser Permanente Washington Health Research Institute


Kai Yeung, PharmD, PhD, is a pharmacist and pharmaceutical economist with expertise in patient medication-use behaviors, insurance design, and outcomes research. His objective is to develop and evaluate incentives to encourage high-value use of health care services. Dr. Yeung has conducted research evaluating policies focused on specialty drug access, value-based insurance design, the consequences of insurance switching, and financial incentives. He combines applied econometric and cost-effectiveness analysis tools with a clinical understanding of prescription drugs and health insurance design to gain new insights in these areas.

Dr. Yeung has a line of research on designing and evaluating policies that align patient prescription drug out-of-pocket costs with estimated value using cost-effectiveness analysis. He has used econometric methods to quantify the impact of a value-based formulary on patient medication-utilization behavior, health outcomes and health care expenditures from patient and health care payer perspectives. For this work, Dr. Yeung successfully competed for two research grants: a multidisciplinary research training grant from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) and a health services research dissertation grant from the Agency for Healthcare Research and Quality (AHRQ). Different parts of this project were recognized by the International Society for Pharmacoeconomics and Outcomes Research 2014 and 2015 annual meetings as the best student podium presentation award, and the Vancouver Health Economics Methodology 2016 meeting as the best student paper award. Dr. Yeung continues to innovate in the generation and evaluation of this type of benefit design.

Dr. Yeung received his PhD in pharmaceutical economics from the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington and his PharmD from the University of Southern California. During his PharmD training, Dr. Yeung cultivated a broad perspective on the expanded use of evidence and analytics in decision-making, giving him experience in working with a diverse group of health care stakeholders, including:

  • patients (through the practice of clinical pharmacy),
  • health care payers (through Kaiser Permanente Drug Information Services),
  • federal agencies (through AHRQ and U.S. Food and Drug Administration),
  • professional organizations (through the Academy for Managed Care Pharmacy), and
  • international technology assessment organizations (through NIH and Clinical Excellence, UK).

Research interests and experience

  • Health Services and Economics

    Pharmacy benefit design, applied econometrics, healthcare costs, value-based insurance design, cost-effectiveness analysis, behavioral economics, alternative payment models, health policy evaluation

  • Medication Use & Patient Safety

    Pharmacoepidemiology of opioid use, identification of early onset Alzheimer’s disease

  • Behavior Change

    Design and evaluation of incentives for medication adherence

  • Preventive Medicine

    Patient and physician shared savings models to incentivize healthy behavior

Recent publications

Yeung K. Value-based insurance design: current evidence and future directions. J Manag Care Spec Pharm. 2019 Jul;25(7):738-741. doi: 10.18553/jmcp.2019.25.7.738. PubMed

Yeung K, Suh K, Garrison LP Jr, Carlson JJ. Defining and managing high-priced cures: healthcare payers' opinions. Value Health. 2019 Jun;22(6):648-655. doi: 10.1016/j.jval.2018.11.012. Epub 2019 May 17. PubMed

Khilfeh I, Guyette E, Watkins J, Danielson D, Gross D, Yeung K. Adherence, persistence, and expenditures for high-cost anti-inflammatory drugs in rheumatoid arthritis: an exploratory study. J Manag Care Spec Pharm. 2019;25(4):461-467. doi: 10.18553/jmcp.2019.25.4.461. PubMed

Yeung K, Suh K, Basu A, Garrison LP, Bansal A, Carlson JJ. Paying for cures: how can we afford it? managed care pharmacy stakeholder perceptions of policy options to address affordability of prescription drugs. J Manag Care Spec Pharm. 2017 Oct;23(10):1084-1090. doi: 10.18553/jmcp.2017.23.10.1084. PubMed

Yeung K, Li M, Carlson JJ. Using performance-based risk-sharing arrangements to address uncertainty in indication-based pricing. J Manag Care Spec Pharm. 2017 Oct;23(10):1010-1015. doi: 10.18553/jmcp.2017.23.10.1010. PubMed


recent news


6 Value Champions begin tackling medical overuse in the safety net

A new training and mentorship program supports clinicians in doing less of what harms and more of what helps vulnerable patients.



Why does Nora Henrikson study patients’ cost of treatment?

Dr. Henrikson’s Annals of Internal Medicine study describes 3 kinds of cost concerns that can affect cancer care.

research into action


Can targeted flu vaccines lower the risk of hospitalization?

Dr. Paula Lozano explains how a Learning Health System project finds Kaiser Permanente Washington members who could benefit most from preventive services.

Personalized Medicine


Has precision medicine’s time arrived?

Dr. Jennifer McClure reflects on using personalized genetic knowledge to improve health and health care.